|
EP2528618A4
(en)
*
|
2010-01-27 |
2015-05-27 |
Univ Indiana Res & Tech Corp |
GLUCAGON ANTAGONISTE AND GIP AGONISTS CONJUGATES AND COMPOSITIONS FOR THE TREATMENT OF METABOLISM DISEASES AND ADIPOSITAS
|
|
PE20240686A1
(es)
|
2011-06-10 |
2024-04-10 |
Hanmi Science Co Ltd |
Peptidos derivados de oxintomodulina con actividad sobre el receptor de glucagon y el receptor de peptido similar a glucagon de tipo 1 (glp-1)
|
|
PE20230404A1
(es)
|
2011-06-17 |
2023-03-07 |
Hanmi Science Co Ltd |
Un conjugado que comprende oxintomodulina y un fragmento de inmunoglobulina, y uso del mismo
|
|
WO2013006486A2
(en)
|
2011-07-01 |
2013-01-10 |
Ngm Biopharmaceuticals, Inc. |
Compositions, uses and methods for treatment of metabolic disorders and diseases
|
|
RU2610175C2
(ru)
|
2011-09-23 |
2017-02-08 |
Ново Нордиск А/С |
Новые аналоги глюкагона
|
|
KR101968344B1
(ko)
|
2012-07-25 |
2019-04-12 |
한미약품 주식회사 |
옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
|
|
KR101993393B1
(ko)
|
2012-11-06 |
2019-10-01 |
한미약품 주식회사 |
옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
|
|
PE20151421A1
(es)
|
2012-11-06 |
2015-09-24 |
Hanmi Pharm Ind Co Ltd |
Formulacion liquida del conjugado de proteina que comprende la oxintomodulina y un fragmento de inmunoglobulina
|
|
US9290557B2
(en)
|
2012-11-28 |
2016-03-22 |
Ngm Biopharmaceuticals, Inc. |
Compositions comprising variants and fusions of FGF19 polypeptides
|
|
HK1214832A1
(zh)
|
2012-11-28 |
2016-08-05 |
恩格姆生物制药公司 |
用於代謝病症和疾病治療的組合物和方法
|
|
US9273107B2
(en)
|
2012-12-27 |
2016-03-01 |
Ngm Biopharmaceuticals, Inc. |
Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
|
|
MX383664B
(es)
|
2012-12-27 |
2025-03-14 |
Ngm Biopharmaceuticals Inc |
Uso de un péptido para modular la homeostasis de los ácidos biliares o tratamiento de una enfermedad relacionada con los ácidos biliares.
|
|
SI2986313T1
(sl)
*
|
2013-04-18 |
2019-09-30 |
Novo Nordisk A/S |
Stabilni koagonisti GLP-1 / glukagonskega receptorja z dolgotrajnim učinkom za medicinsko uporabo
|
|
LT3004155T
(lt)
*
|
2013-05-28 |
2021-12-27 |
Takeda Pharmaceutical Company Limited |
Peptidų junginys
|
|
WO2015035419A1
(en)
*
|
2013-09-09 |
2015-03-12 |
Hoffmann-La Roche Inc. |
Dosages of gip/glp-1 co-agonist peptides for human administration
|
|
CN105792851B
(zh)
*
|
2013-09-13 |
2023-10-10 |
斯克利普斯研究所 |
修饰的治疗剂及其组合物
|
|
WO2015065897A1
(en)
|
2013-10-28 |
2015-05-07 |
Ngm Biopharmaceuticals, Inc. |
Cancer models and associated methods
|
|
CN112043835B
(zh)
|
2013-12-06 |
2022-10-21 |
韩捷 |
用于含氮和羟基的药物的生物可逆引入基团
|
|
AU2014364589B2
(en)
|
2013-12-18 |
2020-02-27 |
The California Institute For Biomedical Research |
Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
|
|
AR098616A1
(es)
|
2013-12-18 |
2016-06-01 |
Lilly Co Eli |
Péptido para el tratamiento de hipoglicemia severa
|
|
PT3097122T
(pt)
|
2014-01-24 |
2020-07-21 |
Ngm Biopharmaceuticals Inc |
Anticorpos de ligação de domínio 2 de beta klotho e métodos de utilização dos mesmos
|
|
TW201625669A
(zh)
*
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
|
|
US10398758B2
(en)
|
2014-05-28 |
2019-09-03 |
Ngm Biopharmaceuticals, Inc. |
Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
|
|
US10570184B2
(en)
|
2014-06-04 |
2020-02-25 |
Novo Nordisk A/S |
GLP-1/glucagon receptor co-agonists for medical use
|
|
WO2015195509A2
(en)
|
2014-06-16 |
2015-12-23 |
Ngm Biopharmaceuticals, Inc. |
Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
|
|
CA2952905A1
(en)
*
|
2014-08-06 |
2016-02-11 |
Nestec S.A. |
Biomarkers for predicting degree of weight loss
|
|
US10968266B2
(en)
|
2014-09-05 |
2021-04-06 |
University Of Copenhagen |
GIP peptide analogues
|
|
TWI802396B
(zh)
*
|
2014-09-16 |
2023-05-11 |
南韓商韓美藥品股份有限公司 |
長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
|
|
CN114129709A
(zh)
|
2014-10-23 |
2022-03-04 |
恩格姆生物制药公司 |
包含肽变异体的药物组合物及其使用方法
|
|
CR20170164A
(es)
|
2014-10-24 |
2017-08-29 |
Merck Sharp & Dohme |
Coagonistas de los receptores de glucagón y de glp-1
|
|
US10434144B2
(en)
|
2014-11-07 |
2019-10-08 |
Ngm Biopharmaceuticals, Inc. |
Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
|
|
JP2018012644A
(ja)
*
|
2014-11-26 |
2018-01-25 |
武田薬品工業株式会社 |
ペプチド化合物
|
|
KR102418477B1
(ko)
|
2014-12-30 |
2022-07-08 |
한미약품 주식회사 |
글루카곤 유도체
|
|
JO3575B1
(ar)
*
|
2015-01-09 |
2020-07-05 |
Lilly Co Eli |
مركبات مساعد مشترك من gip وglp-1
|
|
KR101669140B1
(ko)
|
2015-04-28 |
2016-10-26 |
(주)케어젠 |
항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도
|
|
WO2017019957A2
(en)
|
2015-07-29 |
2017-02-02 |
Ngm Biopharmaceuticals, Inc. |
Binding proteins and methods of use thereof
|
|
TWI622596B
(zh)
|
2015-10-26 |
2018-05-01 |
美國禮來大藥廠 |
升糖素受體促效劑
|
|
JP6728352B2
(ja)
|
2015-11-09 |
2020-07-22 |
エヌジーエム バイオファーマシューティカルス，インコーポレーテッド |
胆汁酸に関係した障害の治療方法
|
|
AR107890A1
(es)
*
|
2016-03-10 |
2018-06-28 |
Medimmune Ltd |
Co-agonistas de glucagón y de glp-1 para el tratamiento de la obesidad
|
|
WO2017204219A1
(ja)
|
2016-05-24 |
2017-11-30 |
武田薬品工業株式会社 |
ペプチド化合物
|
|
EP3503882A4
(en)
|
2016-08-26 |
2020-07-29 |
NGM Biopharmaceuticals, Inc. |
METHOD FOR TREATING FIBROBLAST GROWTH FACTOR-19-MEDIATED CARCINOMAS AND TUMORS
|
|
CN109200273B
(zh)
*
|
2017-07-04 |
2021-02-19 |
中国药科大学 |
一种多肽用于制备预防或治疗脂肪肝病药物的用途
|
|
JOP20190211A1
(ar)
|
2017-03-31 |
2019-09-15 |
Takeda Pharmaceuticals Co |
ببتيد منشط لمستقبل gip
|
|
PL3630806T3
(pl)
*
|
2017-05-31 |
2024-05-13 |
The University Of Copenhagen |
Analogi peptydów gip o długotrwałym działaniu
|
|
US10470311B2
(en)
*
|
2017-09-28 |
2019-11-05 |
Juniper Networks, Inc. |
Clearance size reduction for backdrilled differential vias
|
|
JP7148605B2
(ja)
|
2017-10-12 |
2022-10-05 |
ノヴォ ノルディスク アー／エス |
医学療法におけるセマグルチド
|
|
KR102379958B1
(ko)
*
|
2018-05-04 |
2022-04-01 |
노보 노르디스크 에이/에스 |
Gip 유도체 및 이의 용도
|
|
CN120754229A
(zh)
*
|
2018-07-23 |
2025-10-10 |
伊莱利利公司 |
使用gip/glp1共激动剂用于治疗的方法
|
|
CN121449721A
(zh)
|
2018-12-03 |
2026-02-03 |
安泰博医药 |
经修饰的gip肽类似物
|
|
CN109379770B
(zh)
*
|
2018-12-11 |
2021-04-06 |
北京百瑞互联技术有限公司 |
蓝牙mesh网络的路径辅助候选节点的优选方法、装置及节点
|
|
AU2020206388B2
(en)
*
|
2019-01-07 |
2022-12-01 |
Vitalixir (Beijing) Co., Ltd |
Novel polypeptide and therapeutic uses thereof
|
|
WO2021083306A1
(zh)
*
|
2019-10-31 |
2021-05-06 |
东莞市东阳光生物药研发有限公司 |
Glp-1/gcg双受体激动剂多肽
|
|
AU2020397917A1
(en)
|
2019-12-04 |
2022-06-23 |
The Scripps Research Institute |
GLP2 receptor agonists and methods of use
|
|
WO2021169512A1
(zh)
*
|
2020-02-24 |
2021-09-02 |
中山大学 |
多肽化合物及其在预防或治疗糖尿病或糖尿病并发症中的应用
|
|
CN116113429A
(zh)
*
|
2020-07-06 |
2023-05-12 |
鸿绪生物医药科技（北京）有限公司 |
新型多肽及其治疗用途
|
|
MX2023000303A
(es)
*
|
2020-07-22 |
2023-02-09 |
Novo Nordisk As |
Coagonistas de los receptores del peptido 1 similar al glucagon (glp-1) y del polipeptido insulinotropico dependiente de glucosa (gip) adecuados para el suministro oral.
|
|
BR112023000229A2
(pt)
*
|
2020-07-22 |
2023-01-31 |
Novo Nordisk As |
Composto, composição farmacêutica, e, peptídeo
|
|
MX2023001599A
(es)
*
|
2020-08-14 |
2023-03-07 |
Hanmi Pharmaceutical Co Ltd |
Composicion farmaceutica que comprende un conjugado de accion prolongada del triple agonista del receptor de glucagon/glp-1/gip.
|
|
WO2022080986A1
(ko)
*
|
2020-10-16 |
2022-04-21 |
한미약품 주식회사 |
Glp-1/gip 이중작용제, 이의 지속형 결합체, 및 이를 포함하는 약학적 조성물
|
|
EP4257597A4
(en)
*
|
2020-12-02 |
2025-04-02 |
Dongbao Purple Star (Hangzhou) Biopharmaceutical Co., Ltd. |
LACTAM-MODIFIED POLYPEPTIDE COMPOUNDS
|
|
CN114891071A
(zh)
*
|
2020-12-08 |
2022-08-12 |
鸿绪生物科技(嘉善)有限公司 |
新型多肽及其治疗用途
|
|
CN114617956B
(zh)
*
|
2020-12-10 |
2023-10-03 |
江苏中新医药有限公司 |
一种高效降糖的蛋白质药物
|
|
IL308392A
(en)
|
2021-05-13 |
2024-01-01 |
Carmot Therapeutics Inc |
G protein-coupled receptor modulators
|
|
MX2023014771A
(es)
*
|
2021-06-09 |
2024-03-19 |
Scripps Research Inst |
Conjugados peptidicos duales gip/glp-1 de accion prolongada y metodos de uso.
|
|
CA3237796A1
(en)
*
|
2021-11-12 |
2023-05-19 |
Zhenbin Li |
Pharmaceutical composition of glp-1 receptor and gip receptor dual agonist, and use thereof
|
|
TW202330584A
(zh)
|
2022-01-20 |
2023-08-01 |
丹麥商諾佛 儂迪克股份有限公司 |
前藥及其用途
|
|
CN116143884B
(zh)
*
|
2023-02-03 |
2023-08-04 |
江苏师范大学 |
一类长效GLP-1/glucagon/GIP受体三重激动剂及其应用
|
|
KR20260005268A
(ko)
*
|
2023-04-23 |
2026-01-09 |
카모트 테라퓨틱스 인크. |
당뇨병 치료
|
|
WO2026046202A1
(zh)
*
|
2024-08-26 |
2026-03-05 |
博瑞生物医药（苏州）股份有限公司 |
Glp-1/gip肽或含有其的药物组合物的用途
|
|
WO2026046328A1
(en)
*
|
2024-08-30 |
2026-03-05 |
Beijing Ql Biopharmaceutical Co., Ltd. |
Dosing regimen of glp-1 conjugates
|